Thank you.
That is the thing. Many times people think that there's one simple solution: Waive the IP rights and everything will be smooth and suddenly the vaccines will become available. That is not the thing. We have to understand all the issues, so that it should not lead to some unintended consequences in the medium- to long-term range.
In addition to IP, we should know what the manufacturing capacity is that is available today that is not being used due to IP issues. The partnerships in the products like these vaccines, which has a lot of science behind it, is probably much more important than the IP itself.
Ambassador, can you tell me, on this unused manufacturing capacity that's been almost bandied about, on how there's a lot of unused manufacturing capacity in developing countries that could be manufacturing COVID vaccines...? While we have to recognize that not all developing countries have any manufacturing capacity, can you just highlight on the issue of whether there is any unused manufacturing capacity?